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I N T R O D U C T I O N
The thiazolidinediones (TZDs; see Fig. 1) are peroxisome 
proliferator–activated receptor  (PPAR) agonists used 
in the treatment of type 2 diabetes mellitus to improve 
target cell insulin sensitivity (Hulin et al., 1996). TZDs 
reduce  plasma  triglyceride,  fatty  acid,  and  insulin   
levels, increase HDL cholesterol levels, and promote   
adipocyte differentiation (Hulin et al., 1996; Fujiwara 
and Horikoshi, 2000; Sarafidis, 2008)—effects that are 
mediated by PPAR-regulated gene transcription.
In  addition  to  the  PPAR-dependent  effects,  TZDs 
have  off-target  effects  that  do  not  appear  to  involve 
changes  in  gene  transcription.  These  effects  include 
acute changes in cellular glucose uptake, inhibition 
of L-type voltage-dependent calcium channels, KATP 
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channels, and voltage-dependent potassium channels, 
as well as inhibition of bile acid transport (Table I).
Many off-target TZD effects involve membrane pro-
teins, which are sensitive to changes in their membrane 
environment (Lee, 2004; Andersen and Koeppe, 2007; 
Marsh, 2008; Lundbæk et al., 2010a), and amphiphiles 
tend to be potent modifiers of membrane protein func-
tion at the concentrations where they alter lipid bilayer 
properties (Hwang et al., 2003; Lundbæk et al., 2004, 
2005, 2010a; Artigas et al., 2006; Søgaard et al., 2006; 
Bruno et al., 2007; Ingólfsson et al., 2007). Because the 
TZDs are amphiphiles, we explored whether they alter 
lipid  bilayer  properties  and  thereby  could  modulate 
membrane protein function.
The “nonspecific” regulation of membrane protein func-
tion by amphiphiles occurs because of the hydrophobic 
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The thiazolidinediones (TZDs) are used in the treatment of diabetes mellitus type 2. Their canonical effects are 
mediated by activation of the peroxisome proliferator–activated receptor  (PPAR) transcription factor. In addi-
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phobic/amphiphilic and adsorb to the bilayer–water interface, which will alter bilayer properties, meaning that 
the TZDs may alter membrane protein function by bilayer-mediated mechanisms. We therefore explored whether 
the TZDs alter lipid bilayer properties sufficiently to be sensed by bilayer-spanning proteins, using gramicidin A 
(gA) channels as probes. The TZDs altered bilayer elastic properties with potencies that did not correlate with 
their affinity for PPAR. At concentrations where they altered gA channel function, they also altered the function 
of voltage-dependent sodium channels, producing a prepulse-dependent current inhibition and hyperpolarizing 
shift in the steady-state inactivation curve. The shifts in the inactivation curve produced by the TZDs and other am-
phiphiles can be superimposed by plotting them as a function of the changes in gA channel lifetimes. The TZDs’ 
partition coefficients into lipid bilayers were measured using isothermal titration calorimetry. The most potent   
bilayer modifier, troglitazone, alters bilayer properties at clinically relevant free concentrations; the least potent   
bilayer modifiers, pioglitazone and rosiglitazone, do not. Unlike other TZDs tested, ciglitazone behaves like a   
hydrophobic anion and alters the gA monomer–dimer equilibrium by more than one mechanism. Our results pro-
vide a possible mechanism for some off-target effects of an important group of drugs, and underscore the impor-
tance of exploring bilayer effects of candidate drugs early in drug development.
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function of changes in the host bilayer properties (e.g., 
Lundbæk and Andersen, 1994; Ashrafuzzaman et al., 
2006; Lundbæk et al., 2010a):
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where nI and nII denote the surface densities of the pro-
teins in state I and II, K
I→
II is the equilibrium constant 
for the I↔II equilibrium, kB is Boltzmann’s constant, 
and T is the temperature in Kelvin.
When amphiphiles adsorb at the bilayer–solution 
interface, they alter many bilayer properties, includ-
ing the intrinsic monolayer curvature (Seddon, 1990; 
Lundbæk et al., 2005) and bilayer elastic moduli (Evans 
et al., 1995; Zhelev, 1998), which will alter Gdef (Fig. 2 B). 
and  energetic  coupling  between  bilayer-spanning  pro-
teins and their host lipid bilayer (Fig. 2 A).
The insertion of a protein into a lipid bilayer will lo-
cally perturb the bilayer organization to deform the bi-
layer,  which  incurs  an  energetic  penalty  (the  bilayer 
deformation energy, Gdef). The difference in bilayer 
deformation energy between different conformations 
(denoted I and II) is the bilayer contribution ( ∆G bil
I II → ) 
to the free energy difference between I and II:
  ∆ ∆ ∆ ∆ ∆ ∆ G G G G G G tot prot def def prot bil
I II I II II I I II I II → → → → = + − = + ( ) . .    (1)
Because Gdef, and thus  ∆G bil
I II → ,  varies as a function 
of the bilayer physical properties (thickness, intrinsic 
monolayer curvature, and the associated elastic moduli), 
the protein’s conformational equilibrium will vary as a 
TA B L e   I
Membrane proteins that are modified by the TZDs
TZD PPAR EC50
a Off-target and effect EC50
b Reference
µM µM
Troglitazone 0.5 ATP-sensitive potassium channel KATP 0.7 Lee et al., 1996
L-type calcium channels 3–4 Nakamura et al., 1998
Ca
2+-activated potassium channel BKCa 20–30
c Knock et al., 1999; Stowers et al., 2000
Delayed rectifier potassium channel Kv1.3 3 Ahn et al., 2007
Acute glucose transport 3
c Preininger et al., 1999
Na
+/H
+ exchange 10
c de Dios et al., 2001
Bile transport (bile salt export pump) 4  
10
c
Funk et al., 2001;  
Snow and Moseley, 2007
Rosiglitazone 0.06–0.09 Voltage-dependent Ca
2+ current 2
c Knock et al., 1999
Ca
2+-activated potassium channels, BKCa 20
c Knock et al., 1999; Stowers et al., 2000
Delayed rectifier potassium channel Kv1.3 18 Ahn et al., 2007
Bile transport 10
c Snow and Moseley, 2007
Pioglitazone 0.6 L-type calcium channels 45 Nakamura et al., 1998
Ciglitazone 3–23 Ca
2+-activated potassium channel BKCa 16 Stowers et al., 2000
Store-operated calcium
+ channels 30
c Kim et al., 2005; Epshtein et al., 2009
Bile transport 5
c Snow and Moseley, 2007
aHenke et al., 1998.
bNominal concentrations, not accounting for drug distribution.
cEffective concentration.
Figure 1.  TZD structures. The TZDs are 
hydrophobic,  with  octanol–water  clogP 
values (calculated from the experimental 
logD7.4) and logD7.4 (experimental) of: 5.3 
and 4.2 for troglitazone, 2.8 and 2.6 for 
rosiglitazone, 3.3 and 3.1 for pioglitazone, 
and 5.7 and 4.6 for ciglitazone (Giaginis 
et al., 2007). Calculated pKa is 6.4 (±0.5) 
for all of the TZDs (Giaginis et al., 2007). 
Structures were drawn using MarvinSketch 
5.0.3 (ChemAxon).  Rusinova et al. 251
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where  M  and  D denote monomeric gA subunits (one 
in each bilayer leaflet) and bilayer-spanning dimers/
conducting channels, and k1 and k1 are the association 
and dissociation rate constants, with the channel dimer-
ization constant (KD) given by k1/k1. Within wide lim-
its, the gA channel structure is remarkably unaffected 
by changes in bilayer environment, but the channel life-
time and appearance frequency vary with changes in 
bilayer thickness, elasticity, and lipid intrinsic curvature 
(Lundbæk et al., 2010a). The channel function’s sensi-
tivity to changes in bilayer properties arises because the 
channel’s hydrophobic length is less than the host bilayer’s 
hydrophobic thickness, such that channel formation 
produces a local bilayer deformation with an associated 
deformation energy (Fig. 2 C). In response to the deforma-
tion and associated Gdef, the bilayer exerts a disjoining 
Changes in bilayer properties will alter membrane pro-
tein function when | ∆G bil
I II → | is a significant (>kBT) con-
tribution to  ∆G tot
I II → ,  in which case changes in  ∆G bil
I II →  will 
alter the energetics and kinetics of the I↔II equilib-
rium. This may provide a mechanistic basis for the widely 
observed “membrane effects” of many drugs (Seeman, 
1972), including the TZDs.
To explore whether the TZDs alter lipid bilayer prop-
erties, we used the gramicidin A (gA) channels as probes 
(Andersen et al., 2007; Lundbæk et al., 2010a). gA 
channels are dimers (Bamberg and Läuger, 1973; Veatch 
et al., 1975), which form by the transmembrane dimer-
ization  of  nonconducting  single-stranded  
6.3-helical 
subunits that reside in each bilayer leaflet (O’Connell 
et al., 1990). The kinetics of gA channel formation and 
disappearance  is  described  by  Bamberg  and  Läuger 
(1973), Zingsheim and Neher (1974), and Rokitskaya 
et al. (1996):
Figure  2.  Membrane  protein–lipid 
bilayer hydrophobic coupling. (A) Hy-
drophobic  interactions  between  inte-
gral membrane proteins and their host 
bilayer  cause  the  lipid  bilayer  (with 
an  unperturbed  hydrophobic  thick-
ness  d0)  and  an  embedded  protein 
(with hydrophobic length l) to adapt 
to each other. Protein conformational 
changes  that  involve  the  protein– 
bilayer boundary, for example, a change 
in  protein  hydrophobic  length,  will   
alter  the  local  bilayer  thickness  to 
match the channel length. Such local 
bilayer deformations, with their associ-
ated  bilayer  compression  and  mono-
layer bending, incur an energetic cost 
(the bilayer deformation energy, Gdef). 
The  total  free  energy  difference  be-
tween different protein conformations 
( ∆ ∆ ∆ G G G tot tot tot
I II II I → = − ) therefore has 
a contribution not only from the pro-
tein  per  se  ( ∆ ∆ ∆ G G G prot prot prot
I II II I → = − )   
but  also  from  the  difference  in  bi-
layer  deformation  energy  associ-
ated  with  the  two  conformations   
( ∆ ∆ ∆ G G G bil def def
I II II I → = − ). The protein 
conformational equilibrium therefore 
varies as a function of the bilayer elastic 
moduli,  protein–bilayer  hydrophobic 
mismatch, and the intrinsic lipid cur-
vature. (B) When amphiphiles adsorb 
to the bilayer–solution interface, they 
alter  bilayer  properties  such  as  thick-
ness (d0), intrinsic curvature (c0), and 
elastic moduli, as well as Gdef. The as-
sociated changes in  ∆Gbil
I II →  will alter 
the  conformational  preference  and 
thus its function. (C) Bilayer-spanning gA channels form by transmembrane dimerization of two 
6.3-helical subunits; channel formation 
is reported as changes in the current through the bilayer. The channel length is less than the unperturbed bilayer thickness, meaning 
that the energetic cost of channel formation—and the single-channel appearance frequency and lifetime—varies with changes in lipid 
bilayer properties. (D) Changes in lipid bilayer properties, such as those caused by the adsorption at the bilayer–solution interface, 
therefore will be reflected in changes in gA lifetimes and appearance frequencies, as indicated in the current trace.252 Bilayer-modifying effects of thiazolidinediones
Single-channel lifetimes () were determined by fitting a single-
exponential distribution (N(t)/N(0) = exp{t/}, where N(t) is 
the number of channels with lifetimes longer than time, t, to the 
survivor histograms of the lifetime distributions using Origin 6.1 
(OriginLab). The reported results are the averages of three to 
five experiments, each with at least 300 events. Changes in chan-
nel appearance frequency (f) are based on single-channel record-
ings (>5 min) immediately before and immediately after adding 
the TZDs. Only experiments where the bilayer remained intact 
after TZD addition were used. The results are reported as mean ± 
SD; in case there are only two observations, the results are re-
ported as mean ± range. Relative lifetime and appearance fre-
quency  changes  were  obtained  by  normalizing  the  values  just 
after to those just before adding the TZD.
From the changes in the time-averaged channel density (= f·) 
one can calculate the changes in the channel dimerization con-
stant (KD) as (Hwang et al., 2003):
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where the subscripts “cntrl” and “TZD” indicate the absence and 
presence of the TZD, and the third equality holds in the limit 
[M] [D]   (when [M] is approximately constant). One can then 
calculate the changes in the free energy of dimerization ( ∆∆Gtot
M D → )   
and, if the TZDs do not alter  ∆Gprot
M D → , the changes in  ∆Gbil
M D → , 
cf. Eq. 1:
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where the right-most relation holds when  ∆∆Gprot
M D → ≈ 0.
The capacitance of DC18:1PC bilayers (area, 1.5 mm
2) was 
measured using the current response to a 2.5-Hz saw tooth poten-
tial of 10-mV peak-to-peak amplitude (Lundbæk et al., 1996).
Fluorescence quench measurements. This method has been de-
scribed elsewhere (Ingólfsson and Andersen, 2010; Ingólfsson et al., 
2010). In brief, DC22:1PC in chloroform was dried and rehydrated 
in fluorophore (ANTS) buffer. Large unilamellar vesicles were 
prepared by passing the rehydrated lipid suspension through 
0.1-µm membrane using a mini-extruder (Avanti Polar Lipids, 
Inc.), and extravesicular ANTS was removed using a desalting col-
umn (PD-10; GE Healthcare). ANTS-loaded vesicles were incu-
bated with gA for 24 h at 12°C. The rate of ANTS fluorescence 
quenching by the gA channel–permeant Tl
+ was recorded with a 
stopped-flow spectrofluorometer (SX.20; Applied Photophysics) 
with dead time of <2 ms. Samples were excited at 352 nm, and the 
fluorescence signal above 455 nm was recorded. Vesicles were in-
cubated with the TZD for 10 min at 25°C before measuring the 
quenching rate. TZDs are hydrophobic and cross the cell mem-
brane to reach PPAR; they likewise will equilibrate between the 
inner and the outer bilayer leaflets. Nine mixing reactions were 
done with each sample. Each reaction was analyzed separately   
using MATLAB v7.9 (The MathWorks Inc.). Quenching rates were 
determined by fitting the first 2–100 ms of the fluorescence time 
course  for  the  individual  reactions  with  stretched  exponential 
(Berberan-Santos et al., 2005):
  F t F F F t ( ) ( ) ( ) ( ) exp ( / ) , = ∞ + − ∞ ( )⋅ − { } 0 0 τ
β    (5)
where F(t) denotes the fluorescence intensity as a function of 
time, t, 0 is a parameter with units of time, and  (0 <  ≤ 1) is a 
measure of the dispersity of the sample. We then determined the 
force (Fdis) on the dimer, and the rate constant for dimer 
dissociation varies with changes in Fdis (e.g., Lundbæk   
et al., 2010a). The adsorption of amphiphiles at the   
bilayer–solution interface alters lipid bilayer elastic mod-
uli and the monolayer-intrinsic curvature, which in turn 
alters Fdis. These changes are observed as increased or 
decreased gramicidin channel lifetimes and appearance 
frequencies (Fig. 2 D).
The TZDs alter lipid bilayer properties, with a rank 
order consistent with previous reports showing trogli-
tazone as the most potent inhibitor of ion channel func-
tion (Knock et al., 1999; Ahn et al., 2007). They also 
inhibit voltage-dependent sodium channels (NaV). Simi-
lar to other amphiphiles (Lundbæk et al., 2005), the 
TZDs cause a hyperpolarizing shift in the steady-state 
availability  curve.  The  concentration  dependence  of 
the TZDs’ effects on NaV is similar to that for gA chan-
nels, and the correlation between the TZD effects on gA 
and NaV channels can be superimposed on the relation 
observed for other amphiphiles (Lundbæk et al., 2005), 
suggesting that some TZD off-target effects are medi-
ated by changes in bilayer properties.
M AT E R I A L S   A N D   M E T H O D S
Gramicidin experiments
Materials.  1,2-dioleoyl-sn-glycero-3-phosphocholine  (DC18:1PC), 
1,2-dieicosenoyl-sn-glycero-3-phosphocholine  (DC20:1PC),  1,2- 
dierucoyl-sn-glycero-3-phosphocholine (DC22:1PC), and cholesterol 
were from Avanti Polar Lipids, Inc. n-Decane (99.9% pure) was 
from ChemSampCo. Troglitazone, rosiglitazone, and ciglitazone 
(≥98% purity) were from Cayman Chemical. Pioglitazone (≥99.3% 
purity) was from Tecoland Corporation. 8-Aminonaphthalene-1,3, 
6-trisulfonate (ANTS) was from Invitrogen. A chain-shortened 
13–amino  acid  left-handed  gA  analogue,  des-D-Val-Gly-gA
 
(gA
(13)), two 15–amino acid analogues of opposite helix sense, 
[Ala
1]gA (AgA(15)) and [D-Ala
1]gA
 (AgA
(15)), and a chain-
extended 17–amino acid analogue, endo-Ala
0a-D-Ala
0b-gA (gA(17)), 
were synthesized and purified as described previously (Greathouse 
et al., 1999). Their sequences are listed in Table S1.
Single-channel current measurements. Planar lipid bilayers were 
formed  at  25  ±  1°C  using  20-mg/ml  suspensions  of  DC18:1PC, 
DC18:1PC/cholesterol (1:1 molar ratio), or DC20:1PC in n-decane 
across a 1–1.5-mm opening in a Teflon partition separating two 
2.5-ml compartments. The chamber and electrode solutions were 
1.0 M NaCl and 10 mM HEPES, pH 7. Single-channel measure-
ments  were  done  at  ±200  mV  using  a  patch-clamp  amplifier 
(3900A; Dagan Corp.) and the bilayer punch method (Andersen, 
1983;  Kapoor  et  al.,  2008).  The  current  signal  was  filtered  at   
2 kHz, sampled at 20 kHz, and digitally filtered at 500 Hz. Single-
channel current transitions were identified as described previ-
ously  (Andersen,  1983)  using  software  written  in  Visual  Basic 
(Microsoft). The gA analogues were added to both sides of the bi-
layer. In most experiments, we used two analogues of different 
length and helix sense, which allowed us to explore the role of 
hydrophobic mismatch. After control records were obtained, we 
added TZD from stock solutions (prepared in DMSO) to each 
side of the bilayer, stirred for 1 min, and equilibrated for 10 min. 
The DMSO concentration never exceeded 0.7% (vol/vol), which 
by itself has no effect on bilayer properties (Ingólfsson and   
Andersen, 2010).  Rusinova et al. 253
modified Eagle’s medium (Invitrogen) supplemented with 10% 
(vol/vol) fetal bovine serum (Invitrogen), 2 mM l-glutamine, 
100 U/ml penicillin, and 100 µg/ml streptomycin (Invitrogen) 
at 37°C under 95% air/5% CO2. Cells were grown on 12-mm glass 
coverslips in 35-mm polystyrene culture dishes and used within 
48–72 h of plating.
Electrophysiology. Endogenous TTX-sensitive Na
+ currents (ND7/23 
cells express a combination of NaV subtypes 1.1, 1.2, 1.6, and 1.7, 
as shown by Western blotting; not depicted) were recorded using 
the whole cell clamp configuration (Hamill et al., 1981). Cover-
slips containing ND7/23 cells were transferred into a small-volume 
open bath chamber (Warner Instruments) and continuously per-
fused  at  2  ml/min  with  a  solution  containing  (in  mM):   
130 NaCl, 10 HEPES, 3.25 KCl, 2 MgCl2, 2 CaCl2, 20 TEACl, and 
5 d-glucose, adjusted to pH 7.4 (with NaOH), and 310 mOsm/kg 
H2O (with sucrose).
Voltage-clamp recordings were done at room temperature   
(23–24°C) using a patch-clamp amplifier (Axopatch 200B; Molec-
ular Devices) with a sampling rate of 20- and 5-kHz low-pass filter. 
Recording pipettes were pulled from borosilicate glass capillaries 
(Sutter Instrument) on a puller (P-97; Sutter Instruments) and 
fire-polished. The pipettes were filled with a solution containing 
(in  mM):  120  CsF,  10  NaCl,  10  HEPES,  10  EGTA,  10  TEACl,   
1 CaCl2, and 1 MgCl2, adjusted to pH 7.3 (with CsOH), and   
310 mOsm/kg H2O (with sucrose). The pipettes had a tip resis-
tance of 1.5–2.5 MΩ. The access resistance, 2–4 MΩ, was further 
decreased using 70–80% series resistance compensation. The ini-
tial whole cell seal resistance was 2–4 GΩ, and recordings were 
discarded if the resistance dropped below 1 GΩ. Liquid–junction 
potentials were not corrected. Capacitive current transients were 
electronically cancelled with the internal amplifier circuitry, and 
leak currents were digitally subtracted online using the P/4 pro-
tocol (Bezanilla and Armstrong, 1977).
The TZDs dissolved in DMSO were diluted in the external per-
fusion buffer to their final concentration before experiments the 
same day. Final DMSO concentrations did not exceed 0.7% (vol/
vol). (1% DMSO has no effect on activation or inactivation; not 
depicted.) The perfusion system consisted of Teflon tubing con-
nected  to  a  200-µm  diameter  perfusion  pipette  positioned  in 
close proximity to the patch-clamped cell. The perfusion rate was 
0.2 ml/min and controlled by a pressurized perfusion system 
(ALA Scientific Instruments).
Stimulation protocols and data analysis. The holding potential 
(Vh) was 80 mV unless otherwise stated. Voltage-dependent in-
hibition of peak inward Na
+ current (INa) by TZDs was analyzed 
using a 10-ms test pulse to 0 mV preceded by a 300-ms prepulse 
alternating to either 130 mV (V0) or the voltage of half-maximal 
inactivation (V1/2 = 68 ± 5 mV), applied every 5 s (Lundbæk et al., 
2004). V1/2 was determined for each cell using the two-pulse 
protocol described below.
For examining Na
+ channel activation, currents were evoked by 
a series of 10-ms pulses ranging from 60 to +70 mV in 10-mV 
steps every 5 s. The conductance (GNa) was calculated as GNa = 
INa/(Vm  Erev), where INa is the peak inward current, Vm is the 
amplitude of the voltage step, and Erev is the reversal potential 
(about +65 mV), as estimated using the Nernst equation and the 
internal and external Na
+ concentrations of 10 and 130 mM, re-
spectively; the recorded Erev varied between 65 and 68 mV and did 
not change with TZD application (not depicted). The normalized 
conductance (G/Gmax, where Gmax is the maximal conductance) 
was plotted versus Vm and fitted with a Boltzmann function:
  G G e z V V k T / / exp ( )/ , max a m a B = + − ⋅ ⋅ − { } ( ) 1 1    (8)
quenching rate at 2 ms using the expression (Berberan-Santos   
et al., 2005):
  k t t ( ) / / . = ( )⋅( )
− ( ) β τ τ
β
0 0
1    (6)
The average quenching rate is the average of these rates. The 
reported values are averages of the quenching rates, normalized 
to rate in the absence of TZDs, for three or more experiments.
Isothermal  titration  calorimetry.  Heats  of  adsorption  were 
measured using an isothermal titration calorimeter (Auto-iTC200; 
Microcal Inc.) with 200-µl sample cell volume and 40-µl syringe 
volume. Large unilamellar DC20:1PC or DC18:1PC vesicles were 
prepared as described above, with the following modifications: 
the  lipid  rehydration  buffer  (150  mM  NaNO3  and  15  mM 
HEPES, pH 7) did not contain ANTS, and the vesicles were not 
incubated with gA. TZDs were diluted from DMSO stocks with 
the lipid rehydration buffer. The DMSO concentration in the 
lipid vesicle solution was adjusted to match the TZD-contain-
ing solution.
The lipid vesicle solution was in the syringe, and the TZD solu-
tion was in the sample cell. Titration of lipid vesicles into the TZD 
solution was done with 2-µl injections (the first 0.2-µl injection 
was not taken into account during analysis). The 150-s interval 
between each injection allowed the signal to return to the base-
line and was sufficient for equilibration of TZDs between the   
inner and outer bilayer leaflets. After 19 injections of 3 mM lipid 
into 30 µM troglitazone, or 10 mM lipid into 200 µM rosiglitazone, 
the lipid concentrations were 460 µM or 1.5 mM, respectively; all 
the TZD was considered to be bound to the lipid vesicles when 
the heat generation in subsequent injections became constant. 
(Ciglitazone and pioglitazone did not produce a measurable sig-
nal.) To control for heat of dilution of buffer and lipid vesicles, lipid   
vesicles were injected into a TZD-free buffer solution. The result-
ing enthalpies were below the detection limit of the instrument 
(Fig. S9); we did not correct for them in the data analysis. The en-
thalpy per injection was determined from the area under the 
curve of that injection using Origin 7 (OriginLab) as adapted by 
Microcal for isothermal titration calorimetry data analysis. The 
partition constant  KP
W L →  and enthalpy of partitioning  ∆HP
W L →  
were obtained by plotting the injection enthalpies versus injec-
tion number and fitting using Eq. 7 (derived according to Wenk 
et al., 1997), assuming that the process can be described as parti-
tioning between two immiscible phases (cf., White et al., 1998):
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where i  is the injection number,δh i A( )the injection enthalpy, V 
is the injection volume, CL is the lipid concentration, L is the molar 
lipid volume, ntot
A is the amount of amphiphile in moles, and VW(0) is 
the initial cell volume. Knowing KP
W L →  and ∆HP
W L →  (assuming HP 
is measurable), the free energy (∆GP
W L → ) and entropy (∆SP
W L → ) of   
partitioning is calculated as  ∆ ∆ ∆ G H T S P
W L
P
W L
P
W L → → → = + ⋅ , where 
∆G RT K P
W L
P
W L → → = − ln( ).
Sodium channel current measurements
Cell culture. The ND7/23 rat dorsal root ganglion/mouse neuro-
blastoma fusion cell line (Sigma-Aldrich) was cultured in Dulbecco’s 254 Bilayer-modifying effects of thiazolidinediones
Fig. S11 shows ciglitazone’s effects on gA single-channel currents in 
DC20:1PC bilayers. Table S1 lists the sequences of the gA analogues 
used in this study. Table S2 lists the NaV peak current inhibition,   
Table S3 lists the V1/2 of steady-state inactivation, and Table S4 lists 
the V1/2 of activation before, during, and after TZD superfusion.
R E S U LT S
Gramicidin experiments
TZDs  alter  gA  channel  function. The TZD effects on gA 
channel function were examined by comparing the gA 
single-channel properties before and after the addition of 
each TZD. The left-handed 13–amino acid gA
(13) and 
the right-handed 15–amino acid AgA(15) analogues form 
channels with characteristic current transition amplitudes, 
marked in Fig. 3 A by red and blue lines for gA
(13) and 
AgA(15), respectively. (Because the two analogues form 
channels having opposite handedness, they do not form 
heterodimers.) Fig. 3 (A–D) shows single-channel activity 
before and after the addition of each TZD.
Troglitazone rosiglitazone and pioglitazone increase 
gA channel activity, the time-averaged number of chan-
nels (Fig. 3, A–C); 6 µM ciglitazone decreased the ac-
tivity of both gA
(13) and AgA(15) channels (bottom 
trace in Fig. 3 D). The TZDs are potent modifiers of gA 
channel function, with effects that vary among the com-
pounds tested.
Changes in gA single-channel properties. The changes in 
gA channel activity reflect changes in the energetics of 
where Va is the potential for half-maximal activation, e is the ele-
mentary charge, and za is the apparent gating valence.
Steady-state fast inactivation, or “Na
+ channel availability,” h in 
Hodgkin and Huxley (1952), was measured using a double-pulse 
protocol with a 300-ms prepulse ranging from 130 to 10 mV in 
10-mV steps, followed by a test pulse to 0 mV. Peak currents dur-
ing the test pulse were normalized to the maximal current (I/Imax, 
where Imax is the maximal current that is elicited at the test poten-
tial), plotted versus the prepulse potential (Vm), and fitted with a 
Boltzmann function:
  I I e z V V k T / / exp ( )/ , max 1/2 m 1/2 B = + − ⋅ ⋅ − { } ( ) 1 1    (9)
where z1/2 and V1/2 denote the apparent gating valence and poten-
tial for half-maximal inactivation.
Statistical significance was assessed by two-tailed paired Student’s   
t test. P < 0.05 was considered statistically significant. Programs 
used for data acquisition and analysis were pClamp 10 (Molecular 
Devices), Excel (Microsoft), and Prism 5.0 (GraphPad Software 
Inc.). Values are reported as mean ± SD unless otherwise stated.
Online supplemental material
Fig. S1 shows TZD’s effects on gA single-channel currents. Fig. S2 
shows ciglitazone’s effects on gA single-channel currents at pH 6, 7, 
and 8. Fig. S3 shows pioglitazone’s effects on gA function at pH 6. 
Fig. S4 shows TZD effects on gA channel lifetimes. Fig. S5 shows 
changes in gA
(13) lifetimes relative to changes in AgA(15) life-
times in the presence of TZDs. Fig. S6 shows relative lifetimes of 
gA
(15) and gA(17) in DC20:1PC bilayers as function of [ciglitazone]. 
Fig. S7 compares the effects of troglitazone and ciglitazone on gA 
activity in the presence and absence of cholesterol in DC18:1PC bilay-
ers. Fig. S8 shows fluorescence quenching traces from stopped-flow 
experiments with ciglitazone and troglitazone. Fig. S9 shows dilu-
tion enthalpies of lipid in TZD-free buffer solution. Fig. S10 shows 
timed control experiments for the NaV inactivation experiments. 
Figure 3.  TZD-induced changes in gA function. Current traces before and after the addition of each of the four TZDs to both sides 
of a DC18:1PC/n-decane bilayer doped with gA
(13) and AgA(15). In each panel, the top trace was recorded before adding the TZD, 
and the bottom trace was recorded after the addition. The colored lines denote the current levels for gA
(13) (red line) and AgA(15) 
(blue line). The four panels show the effects of: (A) 1 µM troglitazone, (B) 30 µM rosiglitazone, (C) 10 µM pioglitazone, and (D) 6 µM 
ciglitazone. Bars, 3 pA and 30 s.  Rusinova et al. 255
reduced f for gA
(13) channels to 50% of control 
with little effect on AgA(15) channels (Fig. 5 H). This 
effect is, at least in part, dependent on channel–bi-
layer hydrophobic mismatch, as ciglitazone reduced f 
for AgA
(15) channels in DC20:1PC/n-decane bilayers 
(not depicted).
Troglitazone and rosiglitazone had larger effects on f 
(Fig. 5, E and F) than on  (Fig. 5, A and B), reflecting 
the greater sensitivity of the gA dimerization rate constant, 
as compared with the dissociation rate constant, to changes 
in bilayer properties (Lundbæk et al., 2005).
The TZDs alter lipid bilayer properties. The results in 
Figs. 3–5 show that the TZDs alter gA channel function. 
The TZDs have quantitatively similar effects on left- and 
gA channel formation. To characterize these changes, 
we examined the TZDs’ effects on gA single-channel 
current  transition  amplitudes,  lifetimes,  and  appear-
ance frequencies. The current transition amplitude 
histograms (Fig. 4, A and B, and Fig. S1), show that 
TZDs—except for ciglitazone, which caused a modest 
increase (Fig. 4 B)—did not alter the conductances of 
gA
(13) or AgA(15) channels at the highest concentra-
tions tested. The lack of effect on the gA single-channel 
conductance  suggests  that  troglitazone,  rosiglitazone, 
and pioglitazone do not bind to, or otherwise interact 
directly with, gA channels.
The conductance changes caused by ciglitazone could 
reflect that ciglitazone is a weak acid (pK of 6.4; 
Giaginis et al., 2007). Adsorption of the anionic form of 
ciglitazone at the bilayer/solution would increase the 
local [Na
+], and thus the single-channel conductance 
(Apell et al., 1979). If so, the ciglitazone-induced con-
ductance should be pH dependent, which it is; at pH 8, 
the conductance increase was greater than at pH 7, and 
at pH 6, there was no conductance increase (Fig. S2). 
These results suggest that the conductance changes oc-
cur because the anionic form of ciglitazone adsorbs at 
the bilayer–solution interface and effectively excludes 
that the conductance changes are a result of changes 
in the interfacial dipole potential. We also examined 
whether  similar  pH-dependent  conductance  changes 
occurred with pioglitazone. They did not (Fig. S3). We 
do not understand why only ciglitazone alters the single-
channel conductance
Troglitazone increased the lifetimes () of both gA
(13) 
and AgA(15) channels with a 50% increase at 1 µM 
(Figs. 4 C and 5 A). Rosiglitazone caused similar increases 
in , but at 30-fold higher concentrations (Figs. S4 B 
and 5 B). Pioglitazone did not alter  at concentrations 
up to 10 µM, its solubility limit (Figs. S4 C and 5 C). 
Ciglitazone caused moderate increases in  at concen-
trations up to 6 µM, where the effect appears to saturate 
(Figs. 4 D and 5 D). (The ciglitazone-induced changes 
in  did not vary as a function of pH; not depicted.)
Similar to many other amphiphiles (Lundbæk et al., 
2005), troglitazone, rosiglitazone, and ciglitazone caused 
larger relative increases in  of gA
(13) as compared 
with AgA(15) channels (Fig. S5, A, B, and D). We return 
to this below.
The TZDs also alter the channel appearance frequen-
cies (f) (Fig. 3). The changes in f were evaluated in experi-
ments in which the bilayer did not break during/after 
the addition of the TZD (Fig. 5, E–H), which limits our 
ability to explore changes caused by troglitazone and 
rosiglitazone above 1 and 30 µM, respectively, because 
bilayers break upon the addition of higher concentra-
tions. 1 µM troglitazone (Fig. 5 E), 30 µM rosiglitazone 
(Fig. 5 F), and 10 µM pioglitazone (Fig. 5 G) increased 
f for gA
(13) and AgA(15) channels, with the larger 
effect on the shorter gA
(13) channels. 6 µM ciglitazone 
Figure 4.  Effects of TZDs on ion permeation and single-channel 
lifetimes. Current transition amplitude histograms for gA
(13) 
and AgA(15) channels before (control) and after the addition of: 
(A) 6 µM troglitazone (TRO) and (B) 6 µM ciglitazone (CIG). 
The vertical lines denote the single-channel current transition 
amplitudes in the absence of the TZD for gA
(13) (red line) 
and AgA(15) (blue line). Single-channel survivor histograms for 
gA
(13) (red line) and AgA(15) (blue line) channels in the pres-
ence of varying concentrations of: (C) troglitazone (TRO) and 
(D) ciglitazone (CIG). Each plot was fitted with a single-exponential 
distribution (dashed gray lines); the average lifetimes () for each 
TZD and concentration are indicated in the panels.256 Bilayer-modifying effects of thiazolidinediones
personal communication). We conclude that ciglitazone 
does not have specific interactions with the bilayer-
spanning single-stranded 
6.3-helical gA dimers. Pio-
glitazone did not alter  at the concentrations tested 
(Fig. 5 C), most likely reflecting its limited solubility 
and rather low logP, and consequently low membrane 
concentration. Yet, pioglitazone increases f with similar 
right-handed gA channels (Fig. 5), and when plotting 
ln{/cntrl}, where “cntrl” denotes results in the absence 
of amphiphile, for gA
(13) channels versus ln{/cntrl} 
for AgA(15) channels (Fig. 6), the results for the TZDs 
and structurally unrelated compounds (Lundbæk et al., 
2010b) are described by a shared linear relation with a 
slope of 1.2. That is, the TZDs conform to the pattern 
observed with other bilayer-modifying amphiphiles, in-
dicating that all of these compounds alter the lifetimes 
by a common mechanism.
This  commonality  shows  that  these  compounds  act 
through a common mechanism and excludes that they 
alter    through  direct  interactions  with  the  bilayer-
spanning 
6.3-helical dimers. Because amphiphiles alter 
lipid bilayer properties, including their elastic moduli 
(e.g., Evans et al., 1995; Zhelev, 1998; Ly and Longo, 
2004; Zhou and Raphael, 2005), the most likely common 
mechanism is that the TZD, like other amphiphiles, alter 
gA channel lifetimes by altering lipid bilayer properties.
The situation is more complicated, however. Although 
the ciglitazone-induced changes in  are consistent with 
bilayer-mediated mechanism (Fig. 6), no change in f of 
AgA(15) channels and a decrease in f for gA
(13) chan-
nels indicate that this compound has additional effects. 
The decreased appearance frequency (for the gA
(13) 
channels) could reflect a shift in the equilibrium be-
tween conducting single-stranded and nonconducting 
double-stranded dimers (Sychev et al., 1993; Greathouse 
et al., 1994; Galbraith and Wallace, 1998), or a shift be-
tween different monomeric conformers. We explored 
this using size-exclusion chromatography (SEC) and 
found no effect on the distribution between single-
stranded and double-stranded conformers (Kapoor, R., 
Figure 5.  TZD-induced changes in single-channel lifetime and appearance frequency. Relative changes in gA
(13) (red squares) and 
AgA(15) (blue circles) channel lifetimes as a function of [TZD], normalized to the lifetimes before TZD addition for: (A) troglitazone   
(TRO), (B) rosiglitazone (ROS), (C) pioglitazone (PIO), and (D) ciglitazone (CIG; n = 4–7). The appearance frequency after is nor-
malized to the appearance frequency before the addition of the TZD: (E) 1 µM troglitazone (TRO), (F) 30 µM rosiglitazone (ROS),   
(G) pioglitazone (PIO), and (H) ciglitazone (CIG; n = 2–4).
Figure 6.  Changes in gA
(13) channel lifetimes (13) as a func-
tion of the corresponding changes in AgA(15) channel lifetimes 
(15). Gray data are from Lundbæk et al. (2010b). The colored re-
sults are from this study; each point represents the average value 
from two to seven experiments. Color code: olive, troglitazone 
(TRO); pink, rosiglitazone (ROS); orange, ciglitazone (CIG); 
gray, pioglitazone (PIO). Linear fit (solid line) to the data points 
has a slope of 1.24 (r = 0.997).  Rusinova et al. 257
and Andersen, 2000; Partenskii and Jordan, 2002) will   
alter the kinetics and energetics of gA channel formation 
(Lundbæk et al., 2010a).
From the changes in f (= k1·[M]
2) and  (= 1/ k1), one 
can calculate the changes in the time-averaged channel 
density, KD (see Materials and methods). Table II sum-
marizes the TZD-induced changes in f· and ∆∆Gtot
M D →  for 
troglitazone, rosiglitazone, pioglitazone, and ciglitazone. 
In the case of troglitazone and rosiglitazone, the TZDs 
appear  to  act  through  a  bilayer-mediated  mechanism 
(meaning that  ∆∆Gprot
M D → ≈ 0) and  ∆∆ ∆∆ G G bil tot
M D M D → → ≈ .
In response to the bilayer deformation and associated 
∆Gbil
M D → , the bilayer exerts a disjoining force (Fdis) on the 
channels. Fdis varies a function of the hydrophobic mis-
match (d0  l), the elastic coefficients HB and HX, and 
the intrinsic monolayer curvature c0 (see Eq. A5):
  F H d l H c dis B X = ⋅ ⋅ − ( )− ⋅ 2 0 0.   (10)
The relative increases in  for the gA
(13) channels 
were larger than for the AgA(15) channels (Figs. S5 A, B, 
and D, and 6), meaning that the hydrophobic mismatch-
dependent term in Eq. 10 contributes to the changes in 
Fdis (and  ∆Gbil
M D → ). Changes in HB·(l  d0) could be a re-
sult of changes in HB or d0 (the gA channel structure, 
and thus l, is insensitive to changes in bilayer thickness; 
Wallace et al., 1981; Katsaras et al., 1992). The changes in 
HB can be estimated by comparing the relative change 
in the lifetimes of the longer and shorter channels 
(Lundbæk et al., 2010a):
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where the subscripts 13 and 15 denote the two channel 
types. Using Eq. 11, we find that 6 µM troglitazone and 
200 µM rosiglitazone decrease HB by 4 kJ/(mole·nm
2) 
or 1.6 kBT/nm
2; 1 µM troglitazone and 30 µM rosigli-
tazone  decrease  HB  by  1.5  kJ/(mole·nm
2)  or  0.6 
kBT/nm
2. These changes in bilayer elasticity, although 
small compared with HB for DC18:1PC/n-decane bilayers 
(56 kJ/(mole·nm
2) or 22.6 kBT/nm
2; Lundbæk et al., 
2010a), are sufficient to account for the changes in bi-
layer deformation energy (see Discussion). (Similar esti-
mates were not possible for pioglitazone and ciglitazone 
because the lifetime changes were small, and the esti-
mates were susceptible to even minor experimental noise. 
effects on right- and left-handed channels (Fig. 5 G). 
We do not understand why, but note that pioglitazone 
is completely inert in cholesterol-containing bilayers 
(see below), effectively excluding specific pioglitazone–
gA interactions.
The TZDs do not alter bilayer thickness. The TZD-induced 
changes  in  gA  channel  function  could  result  from 
changes in bilayer thickness. Bilayer thinning will result 
in capacitance increase  C d m r = ε ε 0 0 / ,  where Cm is the 
specific capacitance of the bilayer, o is the permittivity 
of free space, r is the relative dielectric constant, and d0 
is the bilayer hydrophobic thickness. We determined 
the  TZDs’  effects  on  Cm  of  DC18:1PC  bilayers.  Trogli-
tazone (mean ± SD: control, 4.8 ± 0.3 nF/mm
2; 10 µM 
troglitazone, 4.9 ± 0.2 nF/mm
2), rosiglitazone (control, 
4.8 ± 0.2 nF/mm
2; 100 µM rosiglitazone, 4.7 ± 0.3   
nF/mm
2), and pioglitazone (control, 4.9 ± 0.1 nF/mm
2; 
10 µM pioglitazone, 4.9 ± 0.1 nF/mm
2) did not increase 
Cm, demonstrating that the increases in  and f do not 
result from bilayer thinning. 6 µM ciglitazone increased 
Cm 16% (Cm ± SD: control, 4.9 ± 0.2 nF/mm
2; 6 µM 
ciglitazone, 5.7 ± 0.2 nF/mm
2).
The modest ciglitazone-induced increase in  is not 
consistent with the bilayer thinning predicted from the 
capacitance increase. Rather, ciglitazone may act like a 
hydrophobic anion and increase the membrane capaci-
tance by intramembrane charge transfer (Fernández   
et al., 1983). Indeed, ciglitazone increases the bilayer 
conductance. 10 µM ciglitazone increases the steady-
state conductance from 10
8 S/cm
2 to 4 × 10
8 S/cm
2, 
consistent  with  an  aqueous  diffusion-limited  current 
(Le Blanc, 1969). This effect seems to be specific for 
ciglitazone; 6 µM troglitazone had no effect on the bi-
layer conductance.
The TZDs alter the energetics of gA dimerization and lipid 
bilayer elasticity. To minimize the exposure of hydropho-
bic residues to water, gA channels and their host bilayer 
are coupled though hydrophobic interactions, and the 
formation of gA channels of hydrophobic length (l) in 
a bilayer of hydrophobic thickness (d0) causes a local 
change in bilayer thickness, a thinning because l is less 
than d0 (Fig. 2, C and D). Changes in the energetics of 
the  associated  bilayer  deformation  (Huang,  1986;   
Helfrich and Jakobsson, 1990; Nielsen et al., 1998; Nielsen 
TA B L e   I I
TZD induced changes in the free energy of dimerization of gA channels
TZD ∆Gtot gA-(13)
M D →
SD ∆Gtot AgA(15)
M D →
SD
1 µM troglitazone 5.0 0.60 4.0 0.8
30 µM rosiglitazone 5.0 0.2 4.0 0.9
10 µM pioglitazone 4.6 1.2 4.2 1.3
6 µM ciglitazone 1.7 1.7 0.6 2.4
Results in kJ/mole, n = 2–4.258 Bilayer-modifying effects of thiazolidinediones
lipid vesicles, using a fluorescence-based assay for gA 
channel activity (Ingólfsson and Andersen, 2010). To 
monitor gA channel activity, ANTS-loaded large unila-
mellar vesicles are mixed with Tl
+, and the time course 
of fluorescence quenching is recorded (Fig. S8). The 
resulting quenching rate provides a measure of the 
time-averaged  number  of  channels  in  the  vesicles.   
Except for ciglitazone, the TZDs increased the quench-
ing rates, with troglitazone being the most potent and 
pioglitazone the least (Fig. 7). Ciglitazone reduced the 
quenching rate, indicating that the (hydrophobic mis-
match–dependent)  reduction  in  channel  appearance 
rate (Fig. 5 H) dominates over the increase in channel 
The ciglitazone-induced changes in , however, are a   
result of changes in bilayer elasticity, as evident from   
the larger changes in  of the gA
(13) channels, rela-
tive to the AgA(15) channels [Figs. 5 D, S5 D, and 6], 
and  from  the  larger  changes  in    of  the  AgA(15) 
channels in the thicker DC20:1PC/n-decane bilayers 
[Fig. S6], as compared with the DC18:1PC/n-decane bi-
layers [Fig. 5 D].)
Effects of cholesterol. We tested the most and least potent 
bilayer-modifying TZDs (troglitazone and pioglitazone) 
in  cholesterol-containing  bilayers.  Cholesterol  increases 
the bilayer elastic moduli (Evans and Needham, 1987; 
Evans and Rawicz, 1990; Needham and Nunn, 1990), 
meaning that the bilayers are more difficult to deform 
(Evans  and  Needham,  1987;  Lundbæk  et  al.,  1996). 
Similarly to what was found with polyunsaturated fatty 
acids (Bruno et al., 2007), troglitazone has greater effects 
on gA lifetime (Fig. S8 A) and appearance frequency 
(Fig.  S8  B)  in  cholesterol-containing  bilayers.  Piogli-
tazone, which had no effect on  in cholesterol-free bi-
layers, changed neither  (Fig. S7 A), f (Fig. S7 B), nor 
∆Gbil
M D →  (Fig. S7 C).
TZD effects in hydrocarbon-free bilayers. Planar bilayers 
used in the electrophysiological experiments contain 
decane. We also did experiments in hydrocarbon-free 
Figure 7.  Effects of TZDs on the rate of Tl
+-induced fluorescence 
quenching of ANTS encapsulated in large unilamellar vesicles. 
ANTS-containing DC22:1PC vesicles doped with gA were incubated 
for 10 min at 25°C with troglitazone (TRO, olive squares), rosi-
glitazone (ROS, pink squares), pioglitazone (PIO, gray squares), 
or ciglitazone (CIG, orange squares) before mixing with Tl
+ using   
a stopped-flow spectrofluorometer. The quench rate was determined 
by fitting a stretched exponential to the time course of fluores-
cence quenching and determining the rate at 2 ms. Quench rates 
in the presence of the TZD are normalized to control quench   
rate in the absence of TZDs (n = 2–10).
Figure 8.  Partitioning of troglitazone and rosiglitazone into lipid 
bilayers. (A) Heat production as a function of time as 2-µl aliquots 
of a 10-mM lipid vesicle solution is injected into 200 µM of rosi-
glitazone solution. Each injection results in a peak in the energy 
versus time signal (left); the area under the peak corresponds to 
the enthalpy of partitioning for that injection, which is plotted as 
a function of the injection number (, right panel). The solid 
line denotes the fit of Eq. 7 to the results to determine the parti-
tion coefficient (KP
W L → ) and the molar enthalpy of partitioning   
(∆HP
W L → ). (The partitioning of troglitazone was tested by titrat-
ing 30 µM troglitazone with 3 mM lipid.) (B) The partition coeffi-
cient KP
W L →  (solid fill bars) and logKP
W L →  (hatched fill bars) for 
troglitazone (olive) and rosiglitazone (pink). (C)  ∆GP
W L →  (dark 
filled bars),  ∆HP
W L →  (light filled bars), and T S ∆ P
W L →  (open bars) 
for troglitazone (TRO, pink) and rosiglitazone (ROS, pink). n = 3; 
error bars are plotted.  Rusinova et al. 259
Plotting the enthalpy per injection versus the injec-
tion number (Fig. 8 A, right) and fitting Eq. 7 to the re-
sults  allows  for  determining  KP
W L →   (Fig.  8  B)  and 
∆HP
W L → ,  ∆GP
W L → , and T S ⋅
→ ∆ P
W L  (Fig. 8 C). Log KP
W L →  for 
both rosiglitazone (3.2) and troglitazone (4.5) were higher 
than the corresponding LogD7.4 (legend to Fig. 1). The 
thermodynamic profile for the partitioning of troglitazone 
differed from that for rosiglitazone, with entropy dominat-
ing the former and enthalpy the latter, which could reflect 
different locations within the bilayer–solution interface.
TZD effects on NaV on cell membranes
Voltage-dependent inhibition of Na
+ currents (INa). As noted 
above (Table I), the TZDs modulate a variety of mem-
brane proteins. We explored this question further using 
endogenous TTX-sensitive sodium currents in ND7/23 
cells. We have previously found that amphiphiles that 
alter gA channel function (increase f and ) also alter 
the function of voltage-dependent calcium and sodium 
channels (NaV) (Lundbæk et al., 1996, 2004, 2005). We 
therefore  explored  whether  the  TZDs  also  alter  NaV 
function, and we compare their relative potencies on 
NaV and on gA channels as probes of changes in bi-
layer properties.
The TZDs produce a prepulse-dependent inhibition 
of peak INa (Fig. 9 A). This was examined further using 
an alternating pulse protocol (Lundbæk et al., 2004). 
See the bottom of Fig. 9, with conditioning prepulses   
to either 130 mV (V0) or to a voltage at which about 
half the channels are in the fast-inactivated state (V1/2 ≈ 
68 ± 2; see Fig. 9 B). After 5 min of stable baseline 
recordings using this protocol, the TZDs were applied. 
The peak INa during the test pulse was strongly reduced 
by 6 µM troglitazone (Tables III and S2), and the inhibi-
tion was stronger after a prepulse potential to V1/2 than 
to V0 (Fig. 9).
The inhibition was fully reversible when tested from 
V0, but only partially so when tested from V1/2 (Tables 
III and S2). Similar complete and partial reversibility 
lifetime (Fig. 5 D), leading to an overall reduction in 
channel activity.
The relative increases in quenching rates follow the 
pattern  observed  in  the  single-channel  experiments 
(Fig. 5), and the effective concentration ranges and the 
order of TZD potencies are the same in both systems. 
The three TZDs that increase channel activity increase 
the quench rate; ciglitazone, which decreases channel 
activity, decreases the quench rate. The effects of the 
TZDs in hydrocarbon-free membranes are comparable 
to their effects in the presence of decane.
TZD  partitioning  into  lipid  bilayers.  Hydrophobicity,  as 
measured  by  octanol–water  partitioning  (logP:  parti-
tioning of only a single, usually the neutral, species; or 
logD7.4: distribution of all species present at pH 7.4), 
varies among the TZDs, with troglitazone and ciglitazone 
being the most hydrophobic, followed by pioglitazone 
and rosiglitazone (legend to Fig. 1). LogP (or logD) 
thus provides a good estimate for the partition coeffi-
cient of neutral, but not charged, solutes into lipid bi-
layers  (Escher  and  Schwarzenbach,  1996).  For  the 
weakly acidic TZDs, pKa values of 6.4 (Giaginis et al., 
2007), the different electrostatic properties of the bilayer 
interface and the octanol–water phase may cause clogP 
(and logD7.4) to be poor predictors of TZD partitioning 
into bilayers. (pKa of the adsorbed TZDs is likely to be 
higher than the bulk pKa [cf. Peitzsch and McLaughlin, 
1993], and it is unclear what fraction of the TZDs at 
the bilayer–solution interface is charged.) We therefore 
examined the interactions of TZDs with lipid bilayers 
using isothermal titration calorimetry (Heerklotz and 
Seelig, 2000).
Only rosiglitazone and troglitazone produced suffi-
cient heats of partitioning to determine  KP
W L → .  Fig. 8 A 
(left) shows the titration of 200 µM rosiglitazone with 
10-mM  lipid  vesicles  (the  lipid  vesicle  dilution  en-
thalpy is negligible [Fig. S9] and is not considered in 
the data analysis).
Figure 9.  Effect of troglitazone on NaV. 
(A) Macroscopic Na
+ current traces elic-
ited with a pulse to 0 mV in control (left 
panel, black traces) or in the presence 
of 6 µM troglitazone (TRO, right panel, 
olive traces) after a 300-ms prepulse to 
either 130 mV (V0) or to a voltage at 
which approximately half of the channels 
are  in  the  fast-inactivated  state  (V1/2  of 
≈68 mV). (B) Time course of wash-in and 
washout of 6 µM troglitazone (TRO) dur-
ing an alternating pulse protocol applied 
every 5 s in which the prepulse potential 
was either V0 or V1/2 (see inset for pulse 
protocol). The currents are normalized 
to the peak INa in control. Troglitazone inhibits peak INa, and the inhibition is larger after a prepulse to V1/2. The inhibition was fully 
reversible after washout (2 min) when tested after a prepulse to V0 mV; the inhibition was only partially reversible when tested after a 
prepulse to V1/2 (n = 4).260 Bilayer-modifying effects of thiazolidinediones
P < 0.05), and 10 µM pioglitazone (2.3 ± 0.4 mV,   
n = 4, and P < 0.01). Timed control experiment, done 
with  the  control  buffer  solution,  showed  no  shift   
in V1/2 during perfusion of the drug-free “sham drug” 
solution and subsequent “sham wash” (Table III and 
Fig. S10).
To determine whether the TZD-induced changes in 
NaV function could be related to the TZD-induced 
changes in gA channel function, we compared changes 
in V1/2 (Fig. 11 B) to relative changes in gramicidin 
lifetime (Fig. 11 A) for each compound, as plotted in 
Fig. 11 C. The divergent V1/2–[TZD] relations (Fig. 11, 
A and B) can be superimposed when using the TZD-
induced changes in  as a measure for the TZD-induced 
changes in bilayer properties. The V1/2–[TZD] rela-
tions can be superimposed on the V1/2–[amphiphile] 
relations observed previously in studies on capsaicin 
and various detergents (Lundbæk et al., 2005). The 
amphiphile-induced changes in NaV (and gA channel) 
function do not appear to result from direct channel–
amphiphile interactions but from altered channel– 
bilayer interactions.
D I S C U S S I O N
TZDs alter gramicidin channel function at concentra-
tions where they alter the function of many membrane 
proteins, including NaV. The changes in NaV function 
after prepulses to V0 or V1/2, respectively, was observed 
with rosiglitazone. In contrast, the INa inhibition by 
ciglitazone (at 6 µM) did not reverse for either condi-
tioning pulse after washout times that were effective 
for  troglitazone  and  rosiglitazone  (2  min).  Piogli-
tazone caused minimal current inhibition (at 10 µM). 
Fig. 10 compares inhibition of peak INa at the highest 
concentrations tested, with 6 µM troglitazone being 
the strongest and 10 µM pioglitazone being the weak-
est inhibitor.
As in the bilayer experiments, ciglitazone increased 
the capacitance in the whole cell experiments (6 µM 
ciglitazone increased the capacitance 15%, which was 
partially  reversible  after  washout;  not  depicted);  the 
other TZDs had no discernible effect. The ciglitazone-
induced capacitance increase most likely reflects intra-
membrane transfer, as has been observed with other 
hydrophobic anions (Fernández et al., 1983).
Effects of TZDs on NaV inactivation. The steady-state in-
activation  (h  in  the  Hodgkin  and  Huxley,  1952, 
model) curve was determined using a double-pulse 
protocol. All the TZDs produced a hyperpolarizing 
shift in V1/2 (Fig. 10 and Tables III and S3). The larg-
est  shift  was  seen  with  6  µM  troglitazone  (13.2  ±   
4.1 mV, n = 6, and P < 0.001 vs. control), followed by 
200  µM  rosiglitazone  (5.4  ±  1.5  mV,  n  =  3,  and   
P < 0.05), 6 µM ciglitazone (3.0 ± 1.9 mV, n = 4, and 
TA B L e   I I I
The effect of TZDs on peak INa and NaV inactivation
Experimental condition Inhibition of peak INa
Prepulse to V0 Prepulse to V1/2 V1/2 of NaV inactivation
norm INa SD norm INa SD n V1/2 (mV) SD n V1/2 SD
Control 1.00 # 1.00 # 7 68 2.3 6 13 4.1
6 µM troglitazone 0.62
a 0.12 0.36
a 0.13 7 81
a 4.8 6
Wash 0.97 0.05 0.79 0.08 7 73
a 1.8 4
Control 1.00 # 1.00 # 3 70 1.9 3 5 1.5
200 µM rosiglitazone  0.74
b 0.04 0.60
b 0.04 3 76
c 1.5 3
Wash 0.97 0.01 0.76 0.03 3 76 2.1 3
Control 1.00 # 1.00 # 4 72 2.8 4 2 0.4
10 µM pioglitazone 0.97 0.02 0.91
b 0.01 4 74
b 2.5 4
Wash 1.01 0.05 0.89 0.11 4 75
c 3.0 3
Control 1.00 # 1.00 # 7 69 1.5 4 3 1.9
6 µM ciglitazone 0.74
a 0.03 0.72
a 0.11 7 72
c 0.4 4
Wash 0.77 0.04 0.76 0.16 7 71 1.3 4
Control n/a n/a 68 2.5 5 0.3 0.8
Sham drug n/a n/a 68 2.4 5
Sham wash n/a n/a 68 3.2 5
The TZD effects on peak INa after prepulses to 130 mV (V0) or to a voltage at which approximately half the channels are in the fast-inactivated state 
(V1/2). The currents were measured after 1-min perfusion of the drug. Fractional peak INa was normalized to the control value. Right column of the table 
shows the effects of TZDs on steady-state inactivation (or Na
+ channel availability h in the Hodgkin and Huxley, 1952, model). V1/2 values were determined 
in control after 1-min perfusion of the drug and after 2-min washout of the drug. All TZDs significantly shifted V1/2 toward hyperpolarized potentials. 
Stimulation protocols as described in detail in Materials and methods and can also be seen in Fig. 10.
aP < 0.001 versus control by paired two-tailed Student’s t test.
bP < 0.01 versus control by paired two-tailed Student’s t test.
cP < 0.05 versus control by paired two-tailed Student’s t test.  Rusinova et al. 261
concentrations. We next consider the changes in gA 
channel  function,  as  reporters  of  changes  in  bilayer 
properties. We then consider the possible confounding 
effects of n-decane in the planar bilayer experiments. 
Next, we discuss the changes in NaV channel function 
and the relationship between the changes in NaV and 
gA channel function. Finally, we consider how changes 
in  lipid  bilayer  properties  may  constitute  a  general 
mechanism for the off-target effects of hydrophobic/
amphiphilic drugs, including the TZDs.
At what concentrations do the TZDs alter lipid  
bilayer properties?
The TZDs are hydrophobic, with octanol–water parti-
tion coefficients, expressed as clogP or logD7.4, between 
2.8 and 2.6 (for rosiglitazone) and 5.7 and 4.6 (cigli-
tazone; legend to Fig. 1). Thus, they are likely to parti-
tion into bilayers and bind to proteins, and the free 
correlate with the changes in gA channel function, fol-
lowing the pattern observed previously for other amphi-
philes (Lundbæk et al., 2005; Fig. 11), suggesting that 
the TZDs (and the other amphiphiles) alter the func-
tion of both channels through a common mechanism. 
Given that the only common feature of gA and NaV 
channels is that they are embedded in lipid bilayers, the 
most likely common mechanism is that the TZDs ad-
sorb to lipid bilayers to alter their properties. As we dis-
cuss below, the changes in gA and NaV channel function 
occur at TZD concentrations that are similar to (for 
ciglitazone, pioglitazone, and troglitazone) or somewhat 
higher than (rosiglitazone) the plasma concentrations 
in patients (or animals) treated with TZDs.
We first discuss the concentrations at which the TZDs 
alter lipid bilayer properties; TZDs bind to plasma pro-
teins and partition between the electrolyte and bilayer, 
and the free concentrations will be less than the nominal 
Figure 10.  The effect of TZDs on NaV steady-state 
fast  inactivation.  The  left  panels  show  families  of 
Na
+ current traces recorded using a 10-ms test pulse 
to 0 mV after 300-ms conditioning prepulses to po-
tentials ranging from 130 to 10 mV (inset shows 
stimulation protocol) in the absence (black current 
traces)  or  presence  of  the  drug  (colored  current 
traces). Peak INa was normalized to the maximum 
peak INa (elicited after a prepulse to 130 mV), plot-
ted against the prepulse potential and fitted with 
a  two-state  Boltzmann  distribution  (right  panels) 
to determine the voltage for half-maximal inactiva-
tion  (V1/2).  6  µM  troglitazone  (TRO,  olive  traces 
and symbols; V1/2 = 13.2 ± 4.1 mV, n = 6, and P < 
0.001 vs. control by paired two-tailed Student’s t test), 
200 µM rosiglitazone (ROS, pink traces and symbols;   
V1/2 = 5.4 ± 1.5 mV, n = 3, and P < 0.05), 10 µM 
pioglitazone (PIO, gray traces and symbols; V1/2 =   
2.3  ±  0.4  mV,  n  =  4,  and  P  <  0.05),  and  6  µM   
ciglitazone  (CIG,  orange  traces  and  symbols;   
V1/2 = 3.0 ± 1.9 mV, n = 4, and P < 0.05).262 Bilayer-modifying effects of thiazolidinediones
reflect that they localize differently in the bilayer–solution 
interface (as suggested by the different enthalpic and 
entropic contributions to the free energy of portion-
ing). There are 10 lipids in the first shell around a gA, 
so there will be less than one TZD in the first shell, un-
less the TZDs accumulate in the perturbed bilayer adja-
cent to the channel (Andersen et al., 1992; Bruno et al., 
2007). This is unlikely, at least in the case of ciglitazone, 
because the conductance changes do not depend on bi-
layer  thickness  (Fig.  S11),  indicating  that  ciglitazone 
does not partition preferentially into, or out of, the per-
turbed bilayer region (see also, Bruno et al., 2007).   
Although the mTZDs are small, the volume-averaged TZD 
concentrations in the bilayer are high, ranging from 
1 to 15 mM.
To  compare  with  clinical  concentrations,  Table  IV 
lists literature values for the total and free TZD concen-
trations in vivo and in vitro. For troglitazone and cigli-
tazone, the total and free plasma concentrations are 
similar to those in the bilayer experiments. For rosigli-
tazone, the concentrations in the bilayer experiments 
are higher than the plasma concentrations.
Changes in gA channel function and in bilayer properties
Gramicidin channels form by transbilayer dimerization 
of subunits in opposing bilayer leaflets (O’Connell et al., 
1990), which make them suitable to probe for changes 
in bilayer properties (Lundbæk et al., 2010a). gA channel 
function, specifically the channel appearance frequency 
and lifetime, depends on how easy it is to deform the bi-
layer when the channel forms. The less energy required 
for bilayer deformation, the more likely it is that monomer 
drug concentration will be less than the nominal con-
centration  (Søgaard  et  al.,  2006;  Bruno  et  al.,  2007;   
Ingólfsson et al., 2007).
The TZDs are weak acids, and water–octanol parti-
tion coefficients thus may be poor predictors of TZD 
partitioning into bilayers (Escher and Schwarzenbach, 
1996; Avdeef et al., 1998). We therefore measured their 
partition coefficients (Kp) into lipid bilayers using iso-
thermal titration calorimetry. Troglitazone and rosigli-
tazone had sufficient partition enthalpy to allow for the 
determination  Kp.  The  measured  logKps  (Fig.  8)  are 
close to, but higher than, logD7.4. The relationship to 
clogP  is  more  complicated:  for  troglitazone,  logKp  < 
clogP; for rosiglitazone, logKp > clogP (compare Fig. 8 
and legend to Fig. 1). On balance, the results suggest 
that one can use logD7.4 (and clogP) to estimate the bi-
layer partition coefficients (see below). (The planar bi-
layer experiments were done using 1M NaCl, and the 
vesicle experiments were done using 140 mM NaNO3; 
however, ionic strength effects on pKa are small [cf. 
Harned and Owen, 1943; Rossotti and Rossoti, 1961]. 
Similarly, ionic strength effects on partitioning will be 
small because we use zwitterionic DC18:1PC and rather 
low TZD concentrations; salting-in or -out effects like-
wise will be small [cf. Edsall and Wyman, 1958]. We do 
not consider these effects further.)
Knowing the partition coefficients, we can estimate the 
free drug concentrations (Bruno et al., 2007; Ingólfsson 
et al., 2007; see Appendix). At the concentrations listed, 
the mole fractions (mTZD) are small (Table IV), at 0.03 
or  less.  The  different  mole  ratio  of  troglitazone  and 
rosiglitazone needed to alter bilayer properties may   
Figure 11.  Comparison of the TZDs’ effects on NaV and gA channels. (A) The concentration dependence of the TZD-induced changes 
in AgA(15) single-channel lifetimes (/cntrl; n = 1–7; mean ± SD). (In the experiment with 15 µM pioglitazone, there was visible precipi-
tation.) (B) The concentration-dependent shifts in V1/2 for inactivation. (n = 2–6; mean ± SD). (C) The TZD-induced shifts in V1/2 versus 
the natural logarithm of relative changes in AgA(15) single-channel lifetimes. The V1/2 versus ln(/cntrl) relations for troglitazone 
(TRO, olive squares), rosiglitazone (ROS, pink squares), pioglitazone (PIO, gray squares), and ciglitazone (CIG, orange squares) are 
very similar among the TZDs, as well as to the relations observed previously for other bilayer modifiers: Triton X-100 (TX100), -octyl 
glucoside (OG), reduced Triton X-100 (rTX100), Genapol X-100 (GX100), and capsaicin (Lundbæk et al., 2005).  Rusinova et al. 263
right-handed gA channels, which could be because of a 
shift between 
6.3-helical and non–
6.3-helical monomers 
(by a mechanism that does not involve direct gramici-
din–pioglitazone  interactions,  as  pioglitazone  is  com-
pletely inert in cholesterol-containing bilayers; Fig. S7). 
Ciglitazone also has complex effects. The decreases in f 
(Figs. 3 and 5 G) indicate that it alters gA channel func-
tion by a mechanism not involving changes in bilayer 
elasticity. Ciglitazone does not appear to interact with 
the 
6.3-helical dimers (channels); however, nor does 
it alter the equilibrium between single-stranded and 
double-stranded dimers in SEC experiments (Kapoor, 
R., personal communication). SEC experiments, how-
ever, are done at high gA/lipid ratios (1:20–1:100; Bañó 
et al., 1992), where all gA is dimeric, and do not provide 
information about monomers. The decreases in f are 
observed at gA/lipid mole ratios at 1:10
6, where gA is 
mostly monomeric (Durkin et al., 1990). Although bilayer-
embedded gA monomers are 
6.3 helical at high gA/
lipid ratios (He et al., 1994), maybe ciglitazone shifts 
the distribution among the monomers toward non–
6.3-
helical conformers at low gA /lipid ratios.
To check whether the changes in the gA monomer↔
dimer equilibrium could be solely the result of changes 
in bilayer elasticity, we compare two different approaches 
to estimate ∆Gbil
M D → . Based on the changes in  and using 
Eq. 11, 1 µM troglitazone and 30 µM rosiglitazone de-
crease  HB  by  1.5  kJ/(mol·nm
2)  or  0.6  kBT/nm
2.   
Although small in relation to HB, 56 kJ/(mol·nm
2) or 
22 kBT/nm
2 (Lundbæk et al., 2010a), these changes in 
HB are sufficient to account for the measured changes 
in  ∆Gbil
M D → . The hydrophobic mismatch-dependent con-
tribution to  ∆G H H l d bil B B,cntrl
M D → = − ⋅ − ( ) ( ) ( ) 0
2  then can be 
estimated from the changes in HB, knowing that d0 is 
unchanged (see Results) (Fig. 12). This estimate for 
∆Gbil
M D →  can be compared with changes in  ∆Gbil
M D →  esti-
mated using the time-averaged channel concentrations 
and Eq. 4 (Table II).
encounters will result in successful dimerization, and 
the smaller will be the disjoining force acting on the bi-
layer-spanning dimer.
Many amphiphiles, including the TZDs, alter gA chan-
nel appearance frequencies and lifetimes (see Lundbæk 
et al., 2010a), meaning that they alter lipid bilayer proper-
ties when they adsorb at the bilayer–solution interface. 
The common relation between the relative increases in  
for the gA
(13) and AgA(15) channels caused by trogli-
tazone, rosiglitazone, ciglitazone, and other bilayer-modi-
fying amphiphiles (Lundbæk et al., 2010b; Fig. 6) indicates 
that these compounds alter gA channel lifetimes by a com-
mon mechanism that does not involve specific binding.
Ciglitazone’s effects are more complex (Figs. 3 and 5). 
Yet,  the  ciglitazone-induced  changes  in    follow  a   
simple pattern (Figs. 5 D and 6). First, in DC20:1PC bilay-
ers, ciglitazone causes a greater increase in  for the 
shorter  AgA
(15)  compared  with  the  longer  gA(17) 
channels (Fig. S6). Second, the increase in  of AgA
(15) 
channels in DC20:1PC/n-decane bilayers is greater than 
the increase in AgA(15) channels in DC18:1PC/n-decane 
bilayers (Figs. 5 D and S6), meaning that the increase in 
  depends  on  the  channel–bilayer  hydrophobic  mis-
match. Third, ciglitazone alters  of both AgA(15) and 
AgA
(15) channels (Figs. 5 D and S6). Ciglitazone’s   
effects on  vary with hydrophobic mismatch, not the 
detailed  channel  structure,  indicating  that  it  alters   
through increases in bilayer elasticity.
Troglitazone, rosiglitazone, and pioglitazone increased 
f; ciglitazone decreased f. The changes in lifetimes and 
appearance frequencies caused by troglitazone and rosi-
glitazone follow the pattern observed for other amphi-
philes (unpublished data), meaning that these molecules 
shift the monomer–dimer equilibrium toward the dimer 
and thus reduce  ∆Gbil
M D →  (Table II). Pioglitazone did not 
change , indicating that it does not alter bilayer elastic-
ity  at  attainable  concentrations.  It  does,  however,  in-
crease  f  for  both  the  left-handed  gA
(13)  and  the 
TA B L e   I V
TZD concentrations in plasma and in vitro
TZD In vivo/clinical Bilayer experiments Vesicle experiments
Total plasma 
concentration
Free plasma 
concentration
a
Nominal 
[TZD]
b
[TZD]a
c {TZD}m
c mTZD
c [TZD]a
c {TZD}m
c mTZD
c
µM nM µM nM moles/cm
2 nM moles/cm
2
Troglitazone 2–6.4
d 2–64 1 80 5 × 10
13 2 × 10
3 130 9 × 10
13 4 × 10
3
Rosiglitazone 0.4–1.7
d 4–17 30 18,000 6 × 10
12 2 × 10
2 22,100 8 × 10
13 3 × 10
2
Pioglitazone 1.5–4.4
e 36 10 5,600
f 2 × 10
12 10
2 6,900 3 × 10
12 10
2
Ciglitazone 37–90
g 1,900–2,700 1 5
f 5 × 10
13 2 × 10
3 9 10
12 4 × 10
3
aEstimated based on protein binding.
b[TZD] where gA channel function is altered.
cEstimated as described in Eqs. A7–A9.
dFDA (five of the links where the information can be accessed).
eXue et al., 2003.
fBased on clogP (legend to Fig. 1).
gTorii et al., 1984, and Aleo et al., 2005; values for rats.264 Bilayer-modifying effects of thiazolidinediones
Andersen, 1999; Lundbæk et al., 2010a), meaning that 
Fdis is a linear function of d0  l (cf. Eq. A5). That is, the 
expression for  ∆Gbil
M D →  includes a term that is quadratic 
in d0 l (cf. Eq. A4). We further note that the lipid in-
trinsic curvature usually is determined in x-ray scatter-
ing experiments on lipid–hydrocarbon systems (Turner 
and Gruner, 1992; Chen and Rand, 1998), and that the 
hydrocarbons have relatively little effect on the measured 
values  (Chen  and  Rand,  1998).  (n-Decane–containing 
planar bilayers are under tension [e.g., Elliott et al., 
1983], whereas the lipid vesicles used in the fluorescence 
experiments may not be. gA channel lifetimes, however, 
are little affected by changes in membrane tension per se 
[Huang, 1986; Goulian et al., 1998], although channel 
function may be altered by tension-dependent changes 
in bilayer thickness [Goulian et al., 1998].)
Changes in NaV channel function
Previous studies have shown that troglitazone is a more 
potent modifier of ion channel function than the other 
TZDs (Table I). Few studies, however, have compared 
different TZDs’ effects on the same system. We there-
fore compared the effects of the four TZDs on the activ-
ity of endogenous NaV channels in a mammalian cell 
line. The TZDs inhibit peak currents and shift the V1/2 
for inactivation in the hyperpolarizing direction. Timed 
control experiments using a similar perfusion and pulse 
protocol  as  was  used  with  the  TZDs  cause  minimal 
changes in V1/2 (Table III and Fig. S10). Except for cigli-
tazone, the inhibition is reversible when the test cur-
rents are measured after a prepulse to 130 mV, and we 
cannot exclude that ciglitazone interacts directly with 
NaV, in addition to altering bilayer properties. When 
the currents are measured after a prepulse to V1/2, the 
inhibition is not fully reversible, presumably reflecting 
that the shift in V1/2 is not fully reversible. Maybe the 
TZDs accelerate the hyperpolarizing shift in V1/2 that 
occurs in whole cell voltage-clamp studies (e.g., Fernandez 
et al., 1984; Wendt et al., 1992). In any case, the TZDs 
shift  the  equilibrium  distribution  between  noninacti-
vated (closed or open) and inactivated states toward the 
inactivated state(s). (The TZDs also alter NaV activation 
[Table S4] as well as the time course of inactivation and 
recovery from inactivation. These changes will be the 
focus of a forthcoming article [unpublished data].)
Because of redistribution between the aqueous solu-
tion and the membrane and other hydrophobic com-
partments, the free aqueous [TZD] may differ between 
the bilayer system and the whole cell voltage-clamp sys-
tem (Søgaard et al., 2006; Bruno, et al., 2007; Ingólfsson 
et al., 2007; Gingrich et al., 2009). Yet, troglitazone and 
rosiglitazone alter NaV function (Fig. 11 B) at the same 
nominal concentrations and with the same order of   
potency as gA function (Fig. 11 A). When plotting the 
hyperpolarizing shift of V1/2 versus the change in gA 
lifetime (Fig. 11 C), the relationship between the changes 
For AgA(15) channels, l = 2.2 nm (Table S1) and   
d0  ≈  4.0  nm  (Lundbæk  et  al.,  2010b),  and  the 
( ) ( ) H H l d B B,cntrl − ⋅ − 0
2  contribution is estimated to be 4 
to 7 (kJ/mol), comparable to the 4 (kJ/mol) calcu-
lated from changes in time-averaged dimer concentrations 
(Table II). For gA
(13) channels, l = 1.9 nm (Table S1), 
and the  ( ) ( ) H H l d B B,cntrl − ⋅ − 0
2  contribution is estimated 
to be 5 to 9 kJ/(mol·nm
2), somewhat larger than 
the estimates in Table II. The effects of troglitazone 
and rosiglitazone can be accounted for by changes in 
bilayer elasticity.
Adding cholesterol to the bilayer-forming solution al-
tered the TZD bilayer-modifying potency: troglitazone’s 
was increased—both the lifetime and appearance rate 
changes were larger in the cholesterol-containing bilay-
ers (Fig. S7); pioglitazone’s was decreased—neither  
nor f was altered, suggesting that the pioglitazone- 
induced increases in f are not a result of specific interac-
tions with the gramicidins. Changes in bulk membrane 
properties alter the TZDs’ efficacy, although the direc-
tion of the changes in efficacy may vary.
The TZDs have similar effects in hydrocarbon-containing 
and hydrocarbon-free bilayers
TZDs alter lipid bilayer properties in both hydrocarbon-
containing planar bilayers and hydrocarbon lipid vesicles 
(compare Figs. 5, 6, and 7). The effective concentration 
ranges and relative potencies were similar in planar bi-
layers (Figs. 5 and 6), decane-free large unilamellar vesi-
cles (Fig. 7), and in biological membrane as reported by 
changes in NaV channel function (Fig. 11).
This  is  not  surprising.  n-Decane–containing  planar 
bilayers are softer than nominally hydrocarbon-free bi-
layers (Lundbæk and Andersen, 1999), but the ln{}–d0 
relations in planar bilayers are linear (Lundbæk and 
Figure 12.  The troglitazone- (TRO, olive bars) or rosiglitazone- 
(ROS, pink bars) induced changes in the bilayer deformation 
energy, as determined from the changes in HB (the hydrophobic 
mismatch–dependent term in Eq. A4). 1 µM troglitazone and   
30 µM rosiglitazone (n = 4–6).  Rusinova et al. 265
hydrophobic. The concentrations where troglitazone alters 
gA channel function are similar to the clinical plasma 
concentrations (Table IV). Troglitazone alters the func-
tion of many membrane proteins at concentrations 
where it alters bilayer properties (Table I), and some of its 
PPAR-independent  effects,  such  as  vasorelaxation  and 
acute glucose uptake (Fujiwara et al., 1988; Nakamura   
et al., 1998; Fujiwara and Horikoshi, 2000), could arise 
from its bilayer-modifying effects. Troglitazone’s bilayer-
modifying properties also could account for its hepato-
toxicity that may be a result of inhibition of hepatic bile 
acid transport (Snow and Moseley, 2007).
Rosiglitazone and pioglitazone, which have the least 
clogP and logD7.4, are the least bilayer modifying. Piogli-
tazone, the least potent bilayer modifier, has less car-
diovascular side effects than rosiglitazone (Graham   
et al., 2010; Juurlink, 2010; Nissen and Wolski, 2010). 
Rosiglitazone’s clinical side effects, however, occur at 
concentrations where it has minimal bilayer-modifying 
effects (compare Table IV). The bilayer-modifying po-
tency of TZDs, as expressed in changes in gA channel 
function, can be used to predict the likelihood and se-
verity of side effects at the TZDs’ plasma concentrations 
during treatment. But these drugs do, of course, also 
cause side effects through mechanisms unrelated to their 
bilayer effects.
The TZDs are part of a growing library of molecules 
that alter gA channel function (e.g., Lundbæk et al., 
2010a). It has long been known that hydrophobic drugs 
have “membrane effects” (e.g., Seeman, 1972), and the 
bilayer-perturbing  effects  of  hydrophobic  drugs  have 
been characterized using a variety of physicochemical 
probes (Seddon et al., 2009). It has proven difficult, 
however, to relate changes in bilayer properties, as de-
duced from changes in some physicochemical probes, 
to  changes  in  membrane  protein  function,  and  the 
changes in bilayer properties may not be causally re-
lated to the changes in protein function (Spector and 
Yorek, 1985). Many of these difficulties can be overcome 
using gA channels to “sense” aggregate changes in bi-
layer properties and report them as changes in bilayer 
deformation energy (or the disjoining force acting on 
the channels). This is important because bilayer-span-
ning membrane proteins are energetically coupled to 
their  host  bilayer  through  hydrophobic  interactions, 
meaning that there will be a bilayer contribution to the 
energetics  (and  kinetics)  of  protein  conformational 
changes that involve the protein–bilayer boundary, which 
provides for mechanistic insights into hydrophobic 
drugs’ “membrane effects.”
The ability of hydrophobic drugs to alter membrane 
protein function correlates with their ability to alter gA 
channel function (Fig. 11), making it possible to ex-
plore  a  drug  candidate’s  bilayer-perturbing  potential 
early in product development (Leeson and Springthorpe, 
2007; Lundbæk, 2008). It is not sufficient to focus just 
in NaV function and gA channel lifetime is remarkably 
similar—and not just among the TZDs but also among 
other bilayer-modifying compounds. This commonality 
suggests that these structurally diverse compounds alter 
both NaV and gA channel function through a common 
mechanism that involves changes in bilayer properties. 
This does not exclude more direct drug channel inter-
actions, for example, at the channel–bilayer boundary 
(Andersen, 2008), that also may alter the energetic cou-
pling between lipid bilayers and their embedded pro-
teins. Detergents (Deisenhofer et al., 1995) and small 
amphiphiles (Nury et al., 2011), for example, can bind 
at the protein–bilayer interface, which means that they 
can alter protein function by altering the energetic cou-
pling between the bilayer and its embedded ion chan-
nels. We conclude that the TZDs alter the equilibrium 
between  noninactivated  (closed  or  open)  and  inacti-
vated Nav states by changing the bilayer elasticity (the 
bilayer deformation energy associated with the transi-
tion into the inactivated state). That is, the bilayer be-
comes an allosteric regulator of NaV function.
The lipid bilayer as a mediator of off-target drug effects: 
implications for drug development
Our results suggest that gA channels can be used to 
“predict”  whether  amphipathic/hydrophobic  mole-
cules are likely to perturb membrane protein function, 
and at what concentrations. The correlation between 
the changes in gA channel lifetimes and the shift in the 
V1/2 for NaV inactivation is remarkable considering that 
NaV channels are structurally and functionally very dif-
ferent from gA channels. This ability to predict changes 
in NaV channel function from changes in gA function 
suggests that ion channel (membrane protein) func-
tion is regulated by changes in bilayer properties, in-
cluding adaptations in the lipids in immediate contact 
with the protein, strengthening the conclusions of pre-
vious studies (Lundbæk et al., 2005; Artigas et al., 2006; 
Søgaard et al., 2006).
The TZDs were discovered in a search for hypolipid-
emic clofibrate-type compounds (Hulin et al., 1996). 
Ciglitazone was the first TZD to be explored for clinical 
use; it was discontinued during Phase II trials (Scheen, 
2001). It was followed by troglitazone, rosiglitazone, and 
pioglitazone, the three TZDs actually marketed as insulin 
sensitizers.  Roglitazone  was  later  withdrawn  (Scheen, 
2001), and rosiglitazone is restricted in the United States 
(Food and Drug Administration, 2010) and suspended 
in Europe (European Medicines Agency, 2011).
The TZDs modify lipid bilayer properties with the order 
of potency, troglitazone > ciglitazone > rosiglitazone ≥ 
pioglitazone, which differs from their hydrophobicity 
(legend to Fig. 1), ciglitazone > troglitazone > piogli-
tazone > rosiglitazone, and their affinity for PPAR  
(Table I). Ciglitazone and troglitazone are the most   
potent gA channel and NaV modifiers—and the most   266 Bilayer-modifying effects of thiazolidinediones
similar argument holding for c0.) The biquadratic form 
of  ∆Gdef
0  in Eq. A1 thus should be valid quite generally,   
assuming  ∆Gdef
0 0 0 , ( )  = 0, with (keeping the sign con-
vention  for  the  H  coefficients  as  in  Lundbæk  et  al., 
2010a, Eq. 2.6):
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In multi-component bilayers, the derivatives in Eqs. 
A2 and A3 include contributions from the redistribu-
tion of bilayer components, whether it be lipids or hy-
drocarbon, meaning that Eq. A1 should apply also for 
hydrocarbon-containing lipid bilayers, which can be ap-
proximated  as  elastic  bodies  (White  and  Thompson, 
1973; White, 1974; Evans and Simon, 1975; Requena   
et al., 1975).
In Eq. A1, the  − ⋅ H c C 0
2  term is the deformation energy 
associated with embedding an inclusion of length d0 
(no hydrophobic mismatch) in a bilayer with intrinsic 
lipid curvature c0, because of the need for the lipids   
to adapt to the channel. As noted by Fattal and Ben-
Shaul (1993), this expression does not include the loss 
of conformational entropy of the acyl chains adjacent to 
the channel. Using Eqs. A2 and A3, the corresponding 
expression  becomes  ∆ ∆ G G c c def def
0 0 2
0
2
0
2 0 0 1 2 , ( ) , ( )+ ⋅ ∂ ∂ ( )⋅  
where  ∆Gdef
0 0 0 , ( ) is the energetic cost of embedding an 
inclusion of length d0 in a bilayer with c0 = 0, including 
the  loss  of  conformational  entropy.  Whether  using   
Eq. A1 or Eqs. A2 and A3, the  − ⋅ H c C 0
2  term (in Eq. A1) 
or  ∆ ∆ G G c c def def
0 0 2
0
2
0
2 0 0 1 2 , ( ) ( )+ ⋅ ∂ ∂ ( )⋅  (in Eqs. A2 and A3) 
drops out in the expression for  ∆Gbil
M D → :
  ∆G H l d H l d c bil B X
M D → = ⋅ − ( ) + ⋅ − ( )⋅ 0
2
0 0.    (A4)
The bilayer responds to the deformation by imposing a 
disjoining force (Fdis) on the channel (Andersen and 
Koeppe, 2007; Lundbæk et al., 2010a):
  F
G
d l
H d l H c dis
def
B X = −
∂
∂ − ( )
= ⋅ ⋅ − ( )− ⋅
∆
0
0 0 2 ,    (A5)
and changes in Fdis—as a result, for example, of the ad-
sorption of TZDs at the bilayer–solution interface—will 
be observable as changes in :
  τ
τ
δ
TZD
cntrl
dis,TZD dis,cntrl
B
= −
− ( )⋅ 


 



 
exp ,
F F
k T
   (A6)
where  ( << d0  l) is the distance the two monomers 
move  apart  to  reach  the  transition  state  for  channel 
dissociation.
Fdis varies as a function of the channel–bilayer hydro-
phobic mismatch (l  d0) and intrinsic curvature c0, as 
well as the elastic moduli as expressed through the H co-
efficients. These contributions are separable, within the 
on hydrophobicity (“lipophilicity” in the drug develop-
ment  literature),  because  hydrophobicity  per  se  may 
not predict a compound’s bilayer-modifying potential, 
as evident in our results and from a previous study show-
ing that oleic acid has a higher bilayer partition coeffi-
cient than docosahexaenoic acid, yet docosahexaenoic 
acid is the more potent bilayer modifier (Bruno et al., 
2007). A drug must be sufficiently hydrophobic to reach 
its target (Lipinski et al., 2001), and too high hydropho-
bicity is likely to be problematic because the drug may 
partition strongly into lipid bilayers, but increased hy-
drophobicity cannot be equated with increased bilayer-
modifying propensity. It is important to explicitly test 
whether a drug lead is a bilayer modifier using probes 
that sense relevant (for membrane proteins) changes in 
bilayer properties, such as the gA channels.
A P P E N D I X
Energetics of lipid bilayer deformations
The bilayer deformation energy ( ∆Gdef ) associated with 
a local bilayer thinning can be expressed as:
  ∆G H l d H l d c H c def B X C = ⋅ − + ⋅ − ⋅ + ⋅ ( ) ( ) , 0
2
0 0 0
2    (A1)
where HB, HX, and HC are elastic coefficients that are 
functions of bilayer thickness, elastic moduli, and chan-
nel radius (and include contributions from the ener-
getic cost of redistributing the different components in 
multi-component membranes, including redistribution 
of the decane in our planar bilayers), and c0, the intrinsic 
monolayer curvature (Nielsen and Andersen, 2000).
Eq. A1 can be derived from the theory of elastic bilayer 
deformations  (Nielsen  and  Andersen,  2000;  cf.  their 
Eq. 17). The biquadratic structure of Eq. A1 applies 
more generally, however (Andersen and Koeppe, 2007). 
Membrane protein function is regulated by experimen-
tal maneuvers that alter bilayer thickness and intrinsic 
lipid curvature (Andersen and Koeppe, 2007; Tables I 
and II), meaning that  ∆Gdef
0  can be expressed as a func-
tion of (l  d0) and c0, and maybe other terms. Using a 
Taylor expansion in (l  d0) and c0,  ∆Gdef
0  becomes:
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where the first-order terms will be zero when the bilayer 
can be approximated as an elastic body. (The deforma-
tion energy for small decreases in (d0  l) should equal 
that for small increases of equal magnitude, with a     Rusinova et al. 267
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framework provided by Eq. A3, making it possible to fur-
ther explore the TZD-induced changes in bilayer proper-
ties, in particular, whether the changes in bilayer properties 
reflect changes in intrinsic curvature or elasticity. For ex-
ample, if the TZDs cause larger relative changes in  for 
the shorter than for the longer channels, the changes in 
Fdis result, at least in part, from changes in the hydropho-
bic mismatch-dependent term in Eq. A5. Conversely, if the 
TZDs cause similar relative changes in  of the shorter and 
longer channels, the changes in Fdis result primarily from 
changes in the curvature-dependent term in Eq. A5.
Free drug concentrations
Let {TZD}m denote the [TZD] in each leaflet of the mem-
brane (in moles/area) and [TZD]a the aqueous [TZD]:
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2
[ ] .    (A7)
Disregarding TZD adsorbed to the chamber, the con-
servation relation for the TZD becomes:
  [ [ [ , TZD] TZD] TZD] nom aq a aq m lip ⋅ = ⋅ + ⋅ V V V    (A8)
where [TZD]nom is the nominal [TZD] added to the 
aqueous solutions, Vaq is the aqueous volume, and Vlip is 
the volume of the lipid-forming solution. Combining 
Eqs. A7 and A9:
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In our case, Vaq = 5 ml, Vlip ≈ 2 µl, and d0 ≈ 4 nm (Table IV). 
As we could not determine Kp for pioglitazone and 
ciglitazone, we approximate it using clogP.
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